Eli Lilly Corp. diskutieren
Eli Lilly Corp.
WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Aktie / Pharmazeutika / Large Cap /
859,70 €
1,28 %
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Cantor Fitzgerald from $925.00 to $985.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at BMO Capital Markets from $930.00 to $1,100.00. They now have an "outperform" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at UBS Group AG from $895.00 to $1,080.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $1,104.00 price target on the stock, up previously from $886.00.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Citigroup Inc. from $1,250.00 to $1,500.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,150.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Truist Financial Corporation from $1,038.00 to $1,182.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $1,290.00 price target on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wolfe Research from $1,050.00 to $1,250.00. They now have an "outperform" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wells Fargo & Company from $1,100.00 to $1,200.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Northrop Grumman Corp. diskutieren